Raffaele Colombo
@raffcolo.bsky.social
ADCs, targeted therapies, chemistry, biotech, pharma.
Associate Director @ Zymeworks
Associate Director @ Zymeworks
For a summary of how ADC payload class has evolved over time (up to August 2024), see: aacrjournals.org/cancerdiscov...
December 24, 2024 at 4:51 PM
For a summary of how ADC payload class has evolved over time (up to August 2024), see: aacrjournals.org/cancerdiscov...
Sharing for the 🦋 aficionados:
A record of 77 new ADCs entered clinical development in 2024 (including those accepted but not yet started).
Payload class clearly dominated by topo1i with 55 ADCs.
Greater diversity observed for antibody targets, featuring novel TAAs and several bispecific ADCs.
A record of 77 new ADCs entered clinical development in 2024 (including those accepted but not yet started).
Payload class clearly dominated by topo1i with 55 ADCs.
Greater diversity observed for antibody targets, featuring novel TAAs and several bispecific ADCs.
December 24, 2024 at 4:50 PM
Sharing for the 🦋 aficionados:
A record of 77 new ADCs entered clinical development in 2024 (including those accepted but not yet started).
Payload class clearly dominated by topo1i with 55 ADCs.
Greater diversity observed for antibody targets, featuring novel TAAs and several bispecific ADCs.
A record of 77 new ADCs entered clinical development in 2024 (including those accepted but not yet started).
Payload class clearly dominated by topo1i with 55 ADCs.
Greater diversity observed for antibody targets, featuring novel TAAs and several bispecific ADCs.
ADC (in)stabilities:
- Both sacituzumab govitecan (SG) and sacituzumab tirumotecan (sac-TMT) have an unstable carbonate linker (half-life ~24 h) that releases their respective payloads over time
- SG has an additional point of instability (thiol-maleimide conjugation)
Get ready for #SABCS24
- Both sacituzumab govitecan (SG) and sacituzumab tirumotecan (sac-TMT) have an unstable carbonate linker (half-life ~24 h) that releases their respective payloads over time
- SG has an additional point of instability (thiol-maleimide conjugation)
Get ready for #SABCS24
December 10, 2024 at 4:54 AM
ADC (in)stabilities:
- Both sacituzumab govitecan (SG) and sacituzumab tirumotecan (sac-TMT) have an unstable carbonate linker (half-life ~24 h) that releases their respective payloads over time
- SG has an additional point of instability (thiol-maleimide conjugation)
Get ready for #SABCS24
- Both sacituzumab govitecan (SG) and sacituzumab tirumotecan (sac-TMT) have an unstable carbonate linker (half-life ~24 h) that releases their respective payloads over time
- SG has an additional point of instability (thiol-maleimide conjugation)
Get ready for #SABCS24
ADC trivia: what’s the linker stability of the newly approved (by Chinese NMPA) sacituzumab tirumotecan?
1, 2, 3, 4, 5, 6, 7, or 8?
For more info on ADC linker (in)stabilities: aacrjournals.org/cancerdiscov...
1, 2, 3, 4, 5, 6, 7, or 8?
For more info on ADC linker (in)stabilities: aacrjournals.org/cancerdiscov...
November 28, 2024 at 2:38 AM
ADC trivia: what’s the linker stability of the newly approved (by Chinese NMPA) sacituzumab tirumotecan?
1, 2, 3, 4, 5, 6, 7, or 8?
For more info on ADC linker (in)stabilities: aacrjournals.org/cancerdiscov...
1, 2, 3, 4, 5, 6, 7, or 8?
For more info on ADC linker (in)stabilities: aacrjournals.org/cancerdiscov...
Sacituzumab tirumotecan (aka sac-TMT aka SKB264/MK-2870) approved in China for patients with advanced or metastatic triple negative breast cancer (TNBC) who have received at least 2 prior therapies.
This brings the total number of approved ADCs to 13 worldwide (of which 11 by US FDA)!
This brings the total number of approved ADCs to 13 worldwide (of which 11 by US FDA)!
November 27, 2024 at 4:11 PM
Sacituzumab tirumotecan (aka sac-TMT aka SKB264/MK-2870) approved in China for patients with advanced or metastatic triple negative breast cancer (TNBC) who have received at least 2 prior therapies.
This brings the total number of approved ADCs to 13 worldwide (of which 11 by US FDA)!
This brings the total number of approved ADCs to 13 worldwide (of which 11 by US FDA)!
November 21, 2024 at 3:24 AM
Upcoming early-phase ADC data at #ASH24
(including two interesting preclinical ADCs)
66th ASH Annual Meeting (December 7-10, 2024), full program: ash.confex.com/ash/2024/web...
Note: late-breaking abstracts available online on November 25!
#ADC #ADCs
(including two interesting preclinical ADCs)
66th ASH Annual Meeting (December 7-10, 2024), full program: ash.confex.com/ash/2024/web...
Note: late-breaking abstracts available online on November 25!
#ADC #ADCs
November 19, 2024 at 2:47 AM
Upcoming early-phase ADC data at #ASH24
(including two interesting preclinical ADCs)
66th ASH Annual Meeting (December 7-10, 2024), full program: ash.confex.com/ash/2024/web...
Note: late-breaking abstracts available online on November 25!
#ADC #ADCs
(including two interesting preclinical ADCs)
66th ASH Annual Meeting (December 7-10, 2024), full program: ash.confex.com/ash/2024/web...
Note: late-breaking abstracts available online on November 25!
#ADC #ADCs